The agony and ecstasy of "OMIC" technologies in drug development.
about
Farm animal genomics and informatics: an updateAutomated solid-phase peptide synthesis to obtain therapeutic peptidesThe role of toxicoproteomics in assessing organ specific toxicity.Lower urinary tract disease: what are we trying to treat and in whom?Toxicogenomics in regulatory ecotoxicology.Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders.Pharmacogenetics of controlled ovarian hyperstimulation.Role and challenges of proteomics in pharma and biotech: technical, scientific and commercial perspective.Metabonomics in preclinical drug development.Two-dimensional gels for toxicological drug discovery applications.The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics researchA proteomic primer for the clinicianGlobal metabolic profiling and its role in systems biology to advance personalized medicine in the 21st century."Omics" Technologies and the Immune System (a) , (b).The therapeutic monoclonal antibody market.Camelid Single-Domain Antibodies As an Alternative to Overcome Challenges Related to the Prevention, Detection, and Control of Neglected Tropical Diseases.Progress in biopharmaceutical development.
P2860
Q24815021-B19F650C-DAEC-4004-A892-AD6B2664F22FQ27001623-9FD33A60-CE08-4357-920F-EFE6D9F90B8DQ33786700-5AE22BAB-8487-4664-802C-638A1E5144EBQ35545715-E77E01D0-233D-45A6-9E7F-76D45A91AFFCQ35843819-15E01B3C-879E-4EAF-B1BD-378780600095Q36087088-17FD0DD4-958C-4F16-970A-B9ABCDE60CE7Q36249242-6923F882-7F06-42BD-935A-A2F952528330Q36445568-5FAF5A8F-9AB9-4132-84D9-E4CBBDD30A75Q36544940-41C48A0F-477F-458E-AAF4-23D4F93AB87AQ36545048-F525091A-4039-4D46-B8EC-90D23F785C6CQ36667345-5A79893A-3BB0-4808-A2B7-34D1F5B4B9C5Q36698789-C45F4C40-A892-4268-88A3-0F7A07714430Q36816026-38652362-2DD3-4FFE-8C21-6DEBD267D178Q37658722-241F584B-0249-4493-A6A6-199DBB5BF2D3Q38296275-329B3EE0-D619-4DF5-B0AF-100B2B861D2FQ39002539-EB7F2724-F9AD-4D1A-9861-9F7B8CF87225Q48253463-7426840B-DED1-4BA8-A64C-8728CD8824FE
P2860
The agony and ecstasy of "OMIC" technologies in drug development.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The agony and ecstasy of "OMIC" technologies in drug development.
@ast
The agony and ecstasy of "OMIC" technologies in drug development.
@en
type
label
The agony and ecstasy of "OMIC" technologies in drug development.
@ast
The agony and ecstasy of "OMIC" technologies in drug development.
@en
prefLabel
The agony and ecstasy of "OMIC" technologies in drug development.
@ast
The agony and ecstasy of "OMIC" technologies in drug development.
@en
P356
P1476
The agony and ecstasy of "OMIC" technologies in drug development.
@en
P2093
John A Bilello
P356
10.2174/1566524053152898
P577
2005-02-01T00:00:00Z